CN102883750A - 选择性整联蛋白抑制剂 - Google Patents

选择性整联蛋白抑制剂 Download PDF

Info

Publication number
CN102883750A
CN102883750A CN201180021962XA CN201180021962A CN102883750A CN 102883750 A CN102883750 A CN 102883750A CN 201180021962X A CN201180021962X A CN 201180021962XA CN 201180021962 A CN201180021962 A CN 201180021962A CN 102883750 A CN102883750 A CN 102883750A
Authority
CN
China
Prior art keywords
purposes
dosage
conjugate
experimenter
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180021962XA
Other languages
English (en)
Chinese (zh)
Inventor
A·佩皮奥
G·富兰西斯
T·A·耶德诺克
A·查科里安
B·T·维普科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of CN102883750A publication Critical patent/CN102883750A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180021962XA 2010-04-30 2011-05-02 选择性整联蛋白抑制剂 Pending CN102883750A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33012210P 2010-04-30 2010-04-30
US61/330,122 2010-04-30
US39228810P 2010-10-12 2010-10-12
US61/392,288 2010-10-12
US201161516846P 2011-04-08 2011-04-08
US61/516,846 2011-04-08
PCT/US2011/034721 WO2011137418A1 (en) 2010-04-30 2011-05-02 Selective integrin inhibitors

Publications (1)

Publication Number Publication Date
CN102883750A true CN102883750A (zh) 2013-01-16

Family

ID=44260795

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180021962XA Pending CN102883750A (zh) 2010-04-30 2011-05-02 选择性整联蛋白抑制剂

Country Status (8)

Country Link
EP (1) EP2563405A1 (ru)
JP (1) JP2013525435A (ru)
KR (1) KR20130081651A (ru)
CN (1) CN102883750A (ru)
AU (1) AU2011245140A1 (ru)
CA (1) CA2797974A1 (ru)
EA (1) EA201201482A1 (ru)
WO (1) WO2011137418A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2632492B1 (en) * 2010-10-25 2017-10-04 Biogen MA Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
CA3044526A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CN116712540A (zh) 2016-12-14 2023-09-08 比奥拉治疗股份有限公司 使用整联蛋白抑制剂治疗胃肠道疾病
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035563A (zh) * 2004-07-08 2007-09-12 艾伦药物公司 包括聚合物部分的多价vla－4拮抗剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1881982B1 (en) 2005-05-20 2013-11-20 Elan Pharmaceuticals Inc. Imidazolone phenylalanine derivatives as vla-4 antagonists
AU2006269382B2 (en) 2005-07-08 2014-01-16 Biogen Idec Ma Inc. Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds
BRPI0712013A2 (pt) 2006-05-22 2011-12-27 Elan Pharm Inc preparaÇço de conjugados polimÉricos de compostos terapÊuticos, agrÍcolas e aditivos alimentares
US8269009B2 (en) * 2007-12-07 2012-09-18 Elan Pharmaceuticals, Inc. Methods and compositions for treating liquid tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035563A (zh) * 2004-07-08 2007-09-12 艾伦药物公司 包括聚合物部分的多价vla－4拮抗剂

Also Published As

Publication number Publication date
JP2013525435A (ja) 2013-06-20
KR20130081651A (ko) 2013-07-17
AU2011245140A1 (en) 2012-12-20
CA2797974A1 (en) 2011-11-03
WO2011137418A1 (en) 2011-11-03
EP2563405A1 (en) 2013-03-06
EA201201482A1 (ru) 2013-03-29

Similar Documents

Publication Publication Date Title
CN102883750A (zh) 选择性整联蛋白抑制剂
JP2020526534A (ja) 抗増殖化合物及びその使用方法
US7365080B2 (en) Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof
CN104302295A (zh) 用tor 激酶抑制剂治疗癌症
CN105339009A (zh) 用于治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
US20220273651A1 (en) Methods of treating crohn's disease and ulcerative colitis
TW577742B (en) Treatment of attention deficit disorders
Cohen et al. Bosentan therapy for pulmonary arterial hypertension
Wells et al. The pharmacokinetics of enalapril in children and infants with hypertension
MX2007011783A (es) Tratamiento de pacientes psiquiatricos con menor funcion hepatica con paliperidona.
Avanza Jr et al. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan
US20240066026A1 (en) Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
CN102791705B (zh) 用于tsh受体的反向激动剂和中性拮抗剂
CN113242859A (zh) 吡咯并嘧啶化合物的治疗用途及其固体药物组合物
CA3113468A1 (en) Grapiprant unit dosage forms
WO2018201131A1 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
US20220023321A1 (en) Methods of treating chronic kidney disease with dapagliflozin
KR20180129795A (ko) 렌바티닙 및 에베롤리무스를 사용한 신세포 암종의 치료
Ramírez-Salinas et al. Repositioning of ligands that target spike glycoprotein as potential drugs against SARS-CoV-2
US20120059029A1 (en) Selective integrin inhibitors
CA2471543C (en) Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation
Zhao et al. Comparison of antihypertensive drugs amlodipine and perindopril on blood pressure variability after long-term treatment of hypertension induced by apatinib and bevacizumab
Roberge et al. Acute chemical pancreatitis associated with a tricyclic antidepressant (clomipramine) overdose
JP2020519576A (ja) 肝細胞癌の治療
TW564176B (en) Buflomedil for blocking sympathetic alpha-1A adrenoceptor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130116